Windlas Biotech Limited (WINDLAS.NS)

INR 1050.0

(-0.63%)

Market Cap (In INR)

21.94 Billion

Revenue (In INR)

6.3 Billion

Net Income (In INR)

581.87 Million

Avg. Volume

72.42 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
410.0-1198.25
PE
-
EPS
-
Beta Value
0.367
ISIN
INE0H5O01029
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Komal Gupta
Employee Count
-
Website
https://windlasbiotech.com
Ipo Date
2021-08-16
Details
Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic products. The company provides its CMDO products and services across a range of pharmaceutical and nutraceutical conventional, and novel products for customers who market such products under their own brand names to the end users. It also offers manufactures various domestic trade generics and over-the-counter brand product portfolio to cater to nutritional, ayurvedic, wellness, and personal care markets. The company's domestic trade generics and OTC brands products are distributed through the offline channel, such as distributors, stockists, retail pharmacies, and institutional tenders, as well as the online channel, such as various e-commerce platforms. It exports its products primarily to Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. The company was incorporated in 2001 and is based in Gurugram, India.